AU2022210696A1 - Treatment of chronic prurigo - Google Patents

Treatment of chronic prurigo Download PDF

Info

Publication number
AU2022210696A1
AU2022210696A1 AU2022210696A AU2022210696A AU2022210696A1 AU 2022210696 A1 AU2022210696 A1 AU 2022210696A1 AU 2022210696 A AU2022210696 A AU 2022210696A AU 2022210696 A AU2022210696 A AU 2022210696A AU 2022210696 A1 AU2022210696 A1 AU 2022210696A1
Authority
AU
Australia
Prior art keywords
antibody
amino acid
seq
kit
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022210696A
Other languages
English (en)
Inventor
Joel Goldstein
Bret Alan HOLLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of AU2022210696A1 publication Critical patent/AU2022210696A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022210696A 2021-01-22 2022-01-21 Treatment of chronic prurigo Pending AU2022210696A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163140621P 2021-01-22 2021-01-22
US63/140,621 2021-01-22
US202163238688P 2021-08-30 2021-08-30
US63/238,688 2021-08-30
PCT/US2022/013380 WO2022159744A1 (en) 2021-01-22 2022-01-21 Treatment of chronic prurigo

Publications (1)

Publication Number Publication Date
AU2022210696A1 true AU2022210696A1 (en) 2023-09-07

Family

ID=82549848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022210696A Pending AU2022210696A1 (en) 2021-01-22 2022-01-21 Treatment of chronic prurigo

Country Status (6)

Country Link
US (1) US20240109961A1 (https=)
EP (1) EP4281113A4 (https=)
JP (1) JP2024504370A (https=)
AU (1) AU2022210696A1 (https=)
CA (1) CA3207110A1 (https=)
WO (1) WO2022159744A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240117057A1 (en) * 2021-01-22 2024-04-11 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2025250726A1 (en) * 2024-05-30 2025-12-04 Celldex Therapeutics, Inc. Anti-kit antibody dosing and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
NZ630363A (en) * 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CN113975386A (zh) * 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗

Also Published As

Publication number Publication date
EP4281113A4 (en) 2024-11-20
WO2022159744A1 (en) 2022-07-28
CA3207110A1 (en) 2022-07-28
EP4281113A1 (en) 2023-11-29
US20240109961A1 (en) 2024-04-04
JP2024504370A (ja) 2024-01-31

Similar Documents

Publication Publication Date Title
JP7854003B2 (ja) 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
JP6926138B2 (ja) 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
US20240117057A1 (en) Anti-kit antibodies and uses thereof
US20240109961A1 (en) Treatment of chronic prurigo
CN117136070A (zh) 抗-kit抗体及其用途
US20260055193A1 (en) Anti-kit antibody formulations and methods
CN117120089A (zh) 慢性痒疹的治疗
WO2025250726A1 (en) Anti-kit antibody dosing and methods
US20240392005A1 (en) Pd-1/tigit binding proteins for cancer treatment
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白
EA046454B1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТОВ FcRn ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ ГРАВИС
EA052304B1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТОВ FcRn ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ ГРАВИС
HK40026538A (en) Use of fcrn antagonists for treatment of generalized myasthenia gravis